Study overview: Researchers from Alliance Medical (Europe) analyzed oncologic PET-CT scans in patients receiving GLP-1 therapy and observed abnormal fluorodeoxyglucose (FDG) uptake patterns that could easily be mistaken for pathological hot spots. In some cases, what appears to be malignant metabolic activity may, in fact, represent drug-induced metabolic redistributionlikely linked to delayed gastric emptying and altered glucose metabolism caused by GLP-1 agonism
However, significant gaps in research, including inconsistent methodologies, small sample sizes, and limited data on long-term effects, necessitate further robust clinical trials
doi: 10.1002/(SICI)1097-0142(19970215)79:4 3.0.CO;2-2
Phase 3 outcomes will be critical to confirm sustained efficacy, cardiovascular benefit, tolerability at scale, and real-world adherence
Ricucci D, Siqueira JF (2010) Biofilms and apical periodontitis: study of prevalence and association with clinical and histopathologic findings